Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in EDIT — Editas Medicine, Inc.

CIK 1423053 MIAMI, FL
Back to EDIT Full portfolio

Position in EDIT

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$1,636,100
-$46,935 QoQ
Shares Held
662,389
-19.3% QoQ
Ownership
0.677%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in EDIT Over Time

Shares Held

Position Value (USD)

Derivatives in EDIT

reported options exposure · as of Mar 31, 2026
CallValue
$219,336
CallShares
88,800
PutValue
$307,762
PutShares
124,600

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,784,241,435 across 374 Biotechnology names. EDIT ranks #210 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INSM
INSMED Inc
 2,182,571 $356,894,009
2 ONC
BeOne Medicines Ltd.
 1,032,298 $306,561,536
3 BMRN
Biomarin Pharmaceutical Inc
 4,512,634 $254,918,694
4 JAZZ
Jazz Pharmaceuticals plc
 1,259,444 $238,097,887
5 MDGL
Madrigal Pharmaceuticals, Inc.
 453,843 $237,573,195
6 BBIO
BridgeBio Pharma, Inc.
 3,173,940 $235,696,783
7 TERN
Terns Pharmaceuticals, Inc.
 3,218,810 $169,695,662
8 PTGX
Protagonist Therapeutics, Inc
 1,551,900 $163,570,260

All Filings in EDIT

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $1,636,100 662,389
2026-03-31 $219,336 88,800
2026-03-31 $307,762 124,600
2025-12-31 $138,580 67,600
2025-12-31 $111,520 54,400
2025-12-31 $1,683,035 820,993
2025-09-30 $1,256,809 362,193
2025-09-30 $328,609 94,700
2025-09-30 $223,121 64,300
2025-06-30 $1,405,153 638,706
2025-06-30 $248,600 113,000
2025-06-30 $126,940 57,700
2025-03-31 $101,384 87,400
2025-03-31 $61,828 53,300
2025-03-31 $135,349 116,681
2024-12-31 $148,336 116,800
2024-12-31 $64,770 51,000
2024-12-31 $1,170,960 922,016
2024-09-30 $229,493 67,300
2024-09-30 $1,190,942 349,250
2024-09-30 $197,780 58,000
2024-06-30 $255,449 54,700
2024-06-30 $1,033,629 221,334
2024-06-30 $605,699 129,700
2024-03-31 $473,396 63,800
2024-03-31 $335,384 45,200
2024-03-31 $5,312,103 715,917
2023-12-31 $9,123,412 900,633
2023-12-31 $1,618,774 159,800
2023-12-31 $909,674 89,800
2023-09-30 $2,850,197 365,410
2023-09-30 $1,036,620 132,900
2023-09-30 $1,372,800 176,000
2023-06-30 $1,456,710 177,000
2023-06-30 $2,757,905 335,104
2023-06-30 $1,818,007 220,900
2023-03-31 $11,765,437 1,622,819
2023-03-31 $1,057,050 145,800
2023-03-31 $1,841,500 254,000
2022-12-31 $1,589,504 179,200
2022-12-31 $7,267,927 819,383
2022-12-31 $2,763,892 311,600
2022-09-30 $10,953,220 894,871
2022-09-30 $2,448,000 200,000
2022-09-30 $4,044,096 330,400
2022-06-30 $14,872,320 1,257,170
2022-06-30 $3,301,753 279,100
2022-06-30 $3,014,284 254,800
2022-03-31 $5,529,114 290,700
2022-03-31 $11,107,470 583,989

Report a Problem

Category
Description
Email (optional, for follow-up)